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BACKGROUND: Extensive cross talk exists between PI3K/Akt/mTOR and mitogen-activated protein kinase (MAPK)
pathways, and both are upregulated in pancreatic ductal adenocarcinoma (PDAC). Our previous study suggested
that epidermal growth factor receptor inhibitor erlotinib which acts upstream of these pathways acts
synergistically with PI3K inhibitors in PDAC. Horizontal combined blockade upstream and downstream of these
two pathways is therefore explored. METHODS: Erlotinib paired with PI3K inhibitor (BYL719) was tested against
erlotinib plus dual PI3K/mTOR inhibitor BEZ-235, and MEK inhibitor (PD98059) plus BEZ235, on five primary PDAC
cell lines and on two pairs of parent and erlotinib-resistant (ER) cell lines. A range of in vitro assays including cell
proliferation, Western blotting, migration, clonogenic, cell cycle, and apopotic assays was used to test for the
efficacy of combined blockade. RESULTS: Dual downstream blockade of the MAPK and PAM pathways was more
effective in attenuating downstream molecular signals. Synergy was demonstrated for erlotinib and BEZ235 and
for PD-98059 and BEZ-235. This resulted in a trend of increased growth cell cycle arrest, apoptosis, cell
proliferation, and colony and migration suppression. This combination showed more efficacy in cell lines with
acquired resistance to erlotinib. CONCLUSIONS: The additional mTOR blockade provided by BEZ235 in combined
blockade resulted in increased anticancer effect. The hypersensitivity of ER cell lines to additional mTOR blockade
suggested PAM pathway oncogenic dependence via mTOR. Dual downstream combined blockade of MAPK and
PAM pathways with MEK and PI3K/mTOR inhibitor appeared most effective and represents an attractive
therapeutic strategy against pancreatic cancer and its associated drug resistance.
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Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease that is
often diagnosed late, has limited chemotherapeutic options, and has
relatively poor survival. Even though K-Ras; CDKN2A/P16, P53;
and SMAD4 have already been identified as the four core molecular
pathways disrupted in PDAC since the early 2000s, there has been
little advance in targeted therapy in this cancer [1–3]. The only
targeted therapy with proven efficacy to date is the epidermal growth
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the PA.3 trial. In this trial, gemcitabine plus erlotinib delayed
progression by 23% (P = .004) and improved overall survival by 18%
(P = .038). However, the absolute benefit was exceedingly small, with
0.2-month and 10-day gain in median progression-free survival and
overall survival [4]. There are a number of reasons that may
potentially explain the failure of targeted therapy in pancreatic cancer.
One reason has been attributed to intratumoral heterogeneity, where
subclonal population driven by genomic instability acquires frequent
mutations through evolutionary process, resulting in extensive genetic
diversity [5]. This is certainly supported by the findings of the Australian
Pancreatic Genome Initiative, which found over 2000 nonsilent
mutations and 1600 copy number variations in 142 pancreatic cancer
tumors and an average of 26mutations per patient [6]. That said, the vast
majority of homozygous mutations (89%) already existed in the parental
clone of PDAC, and deleterious mutations were more commonly found
in parent than subclones (12.6% vs 8.1%) in a concurrent
primary-metastases study [7]. Another explanation given for the failure
of targeted therapy when used empirically is the failure to identify a
sensitive subgroup due to the lack of predictive biomarkers. The lack of
success is not restricted to targeted therapy such as K-Ras mutation and
EGFR copy number in the use of erlotinib [8], but also with hENT1 in
the use of gemcitabine and SPARC-1 in the use of abraxane
chemotherapy [9–11]. The initial excitement in these biomarker
developments was met with disappointment in validation studies of
prospective phase III trials. This failure emphasizes likely heterogeneity
in drug resistance mechanisms in PDAC and that these mechanisms are
not of key importance in driving growth or drug sensitivity. An
alternative explanation is that the extensive cross talk between redundant
oncogenic pathways in this cancer allows pathway blockade to be easily
circumvented [12]. Of these, cross talk between the mitogen-activated
protein kinase pathway (MAPK) and the PI3K/Akt/mTOR (PAM)
pathway appears particularly important clinically. These appear to be
particularly important for promoting cancer cell growth, proliferation,
survival, and migration (Supp Figure 1). The extensive cross talk
between MAPK and PAM pathways may explain the relative low
efficacy of PI3K inhibitors and the apparent cytostaticity of MEK
inhibitors, which in turn suggests potential benefits in a horizontal
combined blockade (CB) strategy [13,14].
Preclinical studies have demonstrated the effectiveness of
MAPK-PAM co-inhibition in suppressing feedback loops associated
with reactivation of the reciprocal pathway [15] and also established
synergy between the dual inhibitors in B-Raf mutated melanoma,
K-Ras mutated colorectal cancer, PTEN deleted ovarian cancer, lung
cancer, and triple-negative breast cancer [13]. In our previous study,
erlotinib was shown to act synergistically with the PI3Kα inhibitor
BYL-719. In vitro, the combined EGFR-PI3K blockade resulted in
growth cell cycle arrest and apoptosis, and was effective in suppressing
colony formation and cell migration. In vivo, this significantly
inhibited tumor growth compared with control treatment in subrenal
and subcutaneous patient-derived xenograft tumor models [16].
However, the previous study only concentrated on EGFR-insulin-like
growth factor-1 receptor (IGF1R) versus EGFR-PI3K CB. Further-
more, it was uncertain whether PI3K/Akt signaling was the key
molecular pathway conferring onocogenic dependence in pancreatic
cancer or whether a downstream molecular signal such as mTOR was
responsible for it. Given the premise of the cross-interaction between the
MAPK and PAM pathways downstream, the current study was
undertaken to investigate the efficacy of three CBs (EGFR-PI3K,EGFR-PI3K/mTOR, MEK-PI3K/mTOR) on a range of cellular
functions of pancreatic cancer primary and acquired resistant cell lines.
The aim was firstly to investigate the role of additional mTOR inhibition
in CB, secondly to understand the pathophysiology of resistance and
oncogenic dependence in relations to the upstream and downstream
signals of the PAM andMAPK pathways, and thirdly to find the optimal
combined therapy to take into clinical trials.
Materials and Methods
PDAC Cell Lines and Inhibitors
BxPC-3, CFPAC-1, CAPAN-2, MiaPACA-2, and PANC-1 cells
were purchased from ATCC (Manassas, VA). Cell lines were typed by
short tandem repeat profiling, and they conformed to the ATCC
reference standards (CellBank, Westmead, NSW, Australia). Two
erlotinib-resistant (ER) cell lines were subcultured from BxPC-3 and
PANC-1, respectively, after treatment daily with graduating
concentrations of erlotinib (ERL) from 10 to 30 μM over a
10-month period. The final ER cell lines (BxPC-ER and PANC-ER)
showed a 349% and 273% increase in erlotinib IC50 compared with
parent cell lines and were retyped to ensure the same ATCC
standards, screened for contamination, and had IC50 retested after 4
weeks of culturing under normal conditions to ensure the stability of
these cell lines to drug resistance. Erlotinib (Selleckchem, Scoresby,
VIC, Australia), NVP-BYL719 (BYL; Novartis, Basel, Switzerland),
NVP-BEZ235 (BEZ; Novartis, Basel, Switzerland), and PD-98059
(PD; Selleckchem) were dissolved in 100% DMSO as 20-mM,
10-mM, 100-μM, and 4-mM stock solutions, respectively, and
frozen at −20°C. The cell lines and inhibitors used in each respective
experiment are shown in Supplementary Table 1.
Cell Proliferation and Confluence Assays
Cells were seeded at 2 × 103 density in 100 μl final volume in
96-well plates and treated with inhibitors for 72 hours. Cytotoxic
IC50 was first determined for each inhibitor on the five primary
PDAC cell lines, and average IC50av was calculated. The dose
intensity of combined treatment was set at 50% of IC50av of each
respective drug (final concentration). Cells were then treated with
single and combined blockade in a 6 × 6 dosing matrix. The MTT
assay was used to measure viability after 72-hour treatment (BioTek
Synergy HT, Winooski, VT) [17]. For illustration and comparison,
three doubling dosing levels of CB (low, medium, and high
concentration) are presented in column graphs: ERL+ BYL or EY (E
5 μM + Y 2.5 μM, E 10 μM + Y 5 μM, E 20 μM + Y 10 μM), ERL+
BEZ or EB (E 5 μM+B 0.05 μM, E 10 μM+B 0.1 μM, E 20 μM+B
0.2μM), and PD+BEZ or PB (PD5μM+B0.05μM,PD10μM+B
0.1 μM, PD 20 μM + B 0.2 μM). For the study of synergy,
three-dimensional surface plots were fitted with 36 data points of each
of the quadruplicate experiments using spline interpolation (SAS 9.2),
and synergy indices (SIs) with confidence intervals (CIs) were calculated
using nonlinear regression algorithm on a four-parameter Bliss model as
described previously (SAS 9.2) [18]. The data were also analyzed as
percentage of confluence compared with untreated control for
comparison of treatment doses on the confluence of cells.
Western Blotting
Western blotting was conducted as previously described [19]. BCA
Protein Assay (Thermo Fisher, Scoresby, VIC, Australia) was used to
adjust protein concentrations. Dual inhibitors at the highest set
concentration were added for 60 minutes followed by 10 minutes of
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Australia) and IGF-I, 50 ng/ml (Sigma)]. The primary antibodies for
pERK, ERK, pAkt, Akt, pS6, S6, and β-actin were from Cell
Signaling. Secondary antibodies (goat anti-rabbit and goat
anti-mouse) were from Santa Cruz (Mulgrave, VIC, Australia).
Cell Cycle Assay (Flow Cytometry)
Cells were treated with the 3 CB combinations at lowest set
concentration for 48 hours. A total of 300 μl each of flow cytometry
cell cycle mixture was added to the samples after discarding
supernatants from centrifuged samples. The flow cytometry mixture
consisted of 50 μg/ml of propidium iodide (PI), 25 μg/ml of fresh
boiled RNase, and 0.2% Triton X-100 in PBS. Cell cycle distribution
was analyzed by the two-laser four-color FACS Caliburs (BD
Bioscience, San Jose, CA) on the FL2-A channel (designated to
DNA mass by PI). DNA histograms were constructed by Modfit
(Verity, Topsham, ME). The percentage of cells in S-phase [S-phase
fraction (SPF)] was used as the end point of this study.
Apoptosis Assay (Flow Cytomtery)
Cells were treated with the same low-concentration CB combina-
tion and suspended in 300 μl of PBS. To each sample, 2 μl of 2 μM
DiLC1(5) (Sapphire Bioscience, Sydney, Australia) and 10 μg/ml PI
were added for 30 minutes. DiLC1(5) fluorescence was excited at 633
nm, and PI was excited at 488 nm. Apoptotic cells had a clear loss of
mitochondrial signal but retained intact cell membranes and were
located on the lower left quadrant of the apoptosis scatterplots.
Necrotic cells had lost the mitochondrial signal but were stained with
PI because of disrupted cell membranes and were located in the lower
right quadrant. Apoptotic and necrotic cells were analyzed together as
they were usually found on a continuum of cell stress and cell death.
Clonogenic Assay (Anchorage Dependent Growth)
Cells (2000/well) were reseeded after 72-hour exposure to dual
inhibitors and were allowed to grow for 7 to 10 days (10%
confluence). Crystal violet (0.05%) was used to stain the cells, and
images were taken on the LAS-3000 imaging system (Fujifilm,
Brookvale, NSW, Australia). Colonies were counted using Colony
v1.1 software (Fujifilm) and were represented as a percentage of
colonies in untreated controls.
Migration Assay
A total of 8×105 cells were seeded in 96-well ImageLock plates (Essen
Bioscience) to achieve 100%confluence and pretreatedwithmitomycin
(10 μg/ml) as an antiproliferation agent. The Essen Bioscience 96-pin
wound maker was used on the plate to make a uniform scratch in each
well. After three washings, cells were incubated in a fresh medium
mixture consisting of 10% FBS, 10 μg/ml mitomycin, and varying CB
mixtures. The plate was inserted into the IncuCyte imager (Essen
Bioscience), where images were taken every 2 hours for 40 hours using
high-definition phase contrast. Cell migration kinetics were measured
using relative migration density as calculated by the software provided.
Results
Maximal Suppression MAPK and PAM Pathways Signaling
by MEK and PI3K/mTOR Co-inhibition
Among five PDAC cell lines, BxPC-3 and PANC-1 were selected
to perform single versus combined blockade Western blotting
experiments given that the former was RAS wild type and highlysensitive to multiple TKI, whereas the latter was KRAS mutated at
codon 12 and with intrinsic low sensitivity to TKI (Supplementary
Figure 2). In BxPC-3, ERL appropriately reduced EGF-stimulated
pEGFR and pERK at 10 ng/ml, whereas BYL reduced
IGF-stimulated pAkt signals at 50 ng/ml. CB using either drug in
combination with ERL on this cell line was capable of near-complete
inhibition of pERK and pAkt in the presence of both EGF and IGF.
In PANC-1, however, pAkt was either unaffected by ERL, whereas
BYL appropriately decreased downstream signals. EY CB was able to
attenuate most downstream signals including pERK, pAkt, and pS6,
and the inhibition was nearly complete at high dose (ERL 20 μM and
BYL 10 μM). In the EB experiments, BEZ alone hits the targets PI3K
and mTOR, resulting in diminishing of AKT and disappearing of S6
(downstream of mTORC1) at a dose as low as 10 nM in both cell
lines. On the other hand, in the PB experiments, PD was not a very
good MEK inhibitor. It only began to decrease ERK (downstream of
MEK) at 10 μM for BxPC-3, whereas PANC-1 was completely
resistant to its effect on ERK. Despite the fact that PD was inferior to
erlotinib in inhibiting the downstream MAPK pathway, either drug
combined with BEZ resulted in some reduction in pERK signals in
addition to disappearing of pAKT and pS6 in both cell lines. This
confirmed the potency of BEZ by itself or in combination with EGFR
or MEK inhibitor.
ER cell lines characterized by upregulated PAM pathways were
developed previously [16]. The three CBs were further tested against
each other in the two pairs of parent (BxPC-3, PANC-1) and ER cell
lines (BxPC-ER and PANC-ER) (Figure 1A). The parent cell lines
BxPC-3 and PANC-1 demonstrated increased pAkt and pS6 in
response to high concentration EGF (20 ng/ml), which was further
increased after these cell lines had acquired erlotinib resistance. This
enhanced phosphorylation was abrogated by treatment with the three
CBs upstream and downstream ofMAPK and PAM pathways: EY, EB,
and PB. These blockades corresponded to inhibition of EGFR-PI3K
(EY), EGFR-PI3K/mTOR (EB), and MEK-PI3K/mTOR (PB). The
most striking differences between the three CBs was that pAkt and pS6
were attenuated but still present with EGFR-PI3K co-inhibition, but both
phosphorylated signals completely disappeared with EGFR-PI3K/mTOR
and MEK-PI3K/mTOR co-inhibition (Figure 1A, straight arrows). This
appeared more so in the ER cells compared with parent cell lines, implying
that PI3Kα blockade alone was insufficient to switch off PAM pathway in
cell lines with oncogenic shift to PI3K/Akt. pERK remained present in all
three CBs during 20-ng/ml EGF stimulation, but again, the CBs that
additionally inhibitedmTOR(EBandPB) appeared to inhibit itmore than
EY, particularly in PANC-ER compared with PANC-1 (Figure 1A, dotted
arrows). Figure 1B shows mean data from three of experiments of pERK,
pAkt, and pS6 signal response to CB compared with EGF stimulation. As
previously shown in Figure 1A, pAkt and pS6 signals were only weakly
activated by EGF in BxPC-3, implying weak EGFR-PI3K cross talk in this
cell line. Thus, the effects of all three CBs compared with EGF stimulation
were all close to one. For the other cell lines, CB appeared to suppress
downstream molecular signals and in general attenuate pAkt signals more
than pERK and pS6, in keeping with the direct downstream targeting of
PI3K/Akt. Comparing the three CBs, there was certainly some disparity in
the effect of upstream/downstreamCBon pERK and pAkt among the four
cell lines. However, there was a consistent trend toward increasing
suppression of pS6 for CB containing PI3K/mTOR inhibition (EB, PB)
compared with that of PI3K inhibition only (EY) even though this did not
result in statistical significance (Figure 1B, straight arrows). This is in
keeping with the knowledge that pS6 is a downstream effector of
Figure 1. Effect of CB on Akt and S6 activation in pancreatic cancer cell lines. (A) Representative Western blots showing the effect of CB
(high concentration) on pAkt and pS6 in BXPC-3 and PANC-1 and their respective ER cells. The straight arrows highlight the incomplete
attenuation of pAKT and pS6 in the ER cells in response to CB with ERL and BYL. The dotted arrows indicate the reduced level of pERK in
the ER cells with ERL added to BEZ or PD protocols. (B) Mean and SEM of three Western blot experiments comparing phosphorylation
responses to CB (E20Y10 denotes ERL 20 μM+ BYL 10 μM, E20B0.2 denotes ERL 20 μM+ BEZ 0.2 μM, P20B0.2 denotes PD 20 μM+
BEZ 0.2 μM in combination). Results were expressed as a percentage of EGF-stimulated values.
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inhibitor BEZ235. In addition, in PANC-ERwhich had been shown to
be the most strongly Akt-upregulated cell line [16], both pERK and
pAkt also followed the same pattern above (Figure 1B, dotted arrows)
with statistically significant reduction in pERK signal in EB and PB
compared with EY (P = .036 and .048) and in pAkt signal in PB
compared with EY (P = .035). This suggests oncogenic dependency of
this cell line on the downstream MAPK-PAM pathways, making it
susceptible to MEK and mTOR blockade.Growth Cycle Arrest and Apoptosis/Necrosis with
Downstream CB
Because mTOR is intricately involved in cell cycle progression and
cell survival [20,21], cell cycle and apoptosis assays using flow
cytometry were performed to examine the effect of upstream versus
downstream CB. Our previous study had already shown substantial
impact of EY at medium concentration (ERL 10 + 5 μM) on G1 cycle
arrest (down to 18%-22% SPF) and apoptosis (up to 75%-82%
apoptosis plus necrosis), more so compared with single agent
Figure 2. Effect of CB on cell cycle and apoptosis. (A) Effect of the CBs [EY, EB, and PD compared with no treatment (NT)] at low
concentrations of ERL 5 μM,BYL719 2.5 μM,BEZ235 0.05 μM, and PD98059 5 μMonSPFs for ER cells and their parent cell lines. *P b .05.(B)
Comparison of the effects of three CBs on the percentage of necrotic and apoptotic cells. EY denotes erlotinib plus BYL719, EB denotes
erlotinib plus BEZ235, PB denotes PD98059 plus BEZ235. **P b .01.(C) Box-plot of the percentage of cells with necrosis or apoptosis and the
effect of different treatmentswhere NT is no treatment, and blockades of EGFR-PI3K as (EY), EGFR-PI3K/mTOR as (EB) andMEK-PI3K/mTOR as
(PB). Differences between treatments and NT are indicated by * for P b .01 and ** for P b .001 and between EY and PB #= .05. Post hoc LSD
significance analysis indicated all CBs to increase apoptosis and necrosis with a significantly greater effect of PB than EY (P = .05).
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Figure 3. Synergistic effects of CB on cell proliferation. (A) Three-dimensional surface plots and respective SIs of three BCs on five PDAC
cell lines. SI denotes synergy index, shown as mean values with 95% CI. PV denotes proportional viability. Arrow indicates convex
contour on the three-dimensional surface plot suggesting antagonism. Values in bold indicate significant synergy (P b .05). (B) Percentage
confluence under the influence of three CBs compared with control culture medium. Results of 3 doubling concentrations on 5 PDAC cell
lines (ERL 5, 10, 20 μM; BYL 2.5, 5, 10 μM; BEZ 0.05, 0.1, 0.2 μM; PD 5, 10, 20 μM). Mean values ± SEM, *P b .05.
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(ERL 5 μM/BYL 2.5 μM, ERL 5 μM/BEZ 0.05 μM, PD 5 μM/BEZ
0.05 μM) to demonstrate the differences in efficacy. All three CBs
induced decreased SPF, probably reflecting G1-S cell cycle blockade,
and there was a decrease in SPF following PB b EB b EY in three cell
lines (BxPC-ER, PANC-1, PANC-ER), which was statistically
significant in PANC-ER (EB b EY, P = .019; PB b EY, P = .027)
(Figure 2A). A differential response was seen in each of the three CBs
between PANC-ER and PANC-1 (EY, P = .022; EB, P = .035; PB, P =
.050), in keeping with oncogenic dependence on PI3K/Akt in
PANC-ER that was highly upregulated in this pathway.
With apoptosis assays, representative images showed a clear
continuum from apoptosis (bottom left quadrant) to necrosis
(bottom right quadrant) over a 72-hour treatment windowFigure 4. Effect of CB on clonogenic survival. (A) Mean and SEM of co
PB combination on five PDAC cell lines. PD and BEZ were synergistic
three CBs on two pairs of parent and ER cell lines. Efficacy for PB w
three cell lines (P b .05). In both ER cell lines, downstream CBs (EB a
parent cell lines (P b .05). Mean values ± SEM from four experiment(Supplementary Figure 3). Although there was no clear pattern of
increase in apoptosis or necrosis by the three CBs in these cell lines,
taken together, there was an increasing trend toward increasing cell
death by necrosis plus apoptosis caused by these CBs in all cell lines
(PB N EB N EY). Pooled from quadruplicate experiments, the highest
level of necrosis plus apoptosis was seen with the PB combination in
all cell lines from 56% to 80%, followed by EB from 41% to 73%
and lastly with EY from 31% to 65% (one-way analysis of variance,
P = .03) (Figure 2B).When a two-way analysis of variance was
undertaken, the influence of different CBs was highly significant (P =
.002), but ER status was not (P = .3). Post hoc least significant
difference analysis indicated that all CBs increase apoptosis and
necrosis with a significantly greater effect of PB than EY (P = .05)
(Figure 2C). Interestingly, ER status did not reduce the effect of CBlony count as a percentage of untreated control for the effect of the
using the Bliss formula for all cell lines, *P b .05. (B) Comparison of
as lower than that for EY in BxPC-3 cell line but higher in the other
nd PB) suppressed colonies more effectively than in the respective
s.
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despite prior erlotinib therapy.
Synergy and Efficacy Observed in Downstream CB
SIs were calculated and surface plots were created to test the
additive effects of each drug on cell proliferation in the respective CB.
This was tested across five primary PDAC cell lines and shown in
Figure 3A. Significant synergy was found for all CBs in BxPC-3 likely
because of the high sensitivity of this cell line to most drugs.
Comparing the three CBs, significant synergy was found between
ERL and BEZ in 4 out of 5 cell lines except for CAPAN-2, a cell line
that was particularly slow in cell growth and cell death in 72-hour cell
proliferation experiments. Although significant synergy was only
demonstrated between PD and BEZ in two of five cell lines, the SIs
closely approximated that between ERL and BEZ. EY in PANC-1
was the only combination with an SI b1, suggesting antagonism,
which was characterized with a convex three-dimensional surface plot
(straight arrow). However, in the pair of ER cell lines that became
overactivated in PI3K/Akt, the EY combination trended toward
greater synergy in the respective ER line, where mean SI and 95% CI
changed from 0.85 (0.68-1.07) (PANC-1) to 1.44 (0.81-2.56)
(PANC-ER) and from 1.34 (1.17-1.55) (BxPC-3) to 1.71
(1.00-2.89) (BxPC-ER), although these differences were not
significant. Efficacy was studied by plotting the ratio of confluence
of these cell lines treated with CBs compared with controls
(Figure 3B). All cell lines demonstrated a decreasing trend of
confluence or increasing efficacy in cell proliferation suppression in
that PB N EB N EY. Significant differences were demonstrated
between these CBs at most concentrations in CFPAC-1 and
MiaPACA-2 in particular, and in all cell lines, PB significantly
suppressed cell proliferation compared with EY in all concentrations
(all Ps b .05).
Cell survival was studied using clonogenic assays. Given the
slow-growing nature of CAPAN-2 and the lack of significant synergy
found with the PB combination in cell proliferation experiments,
particular focus was taken in testing this CB in clonogenic assays
(Figure 4A). Single blockade by PD or BEZ was able to suppress
colonies by 5% to 53% (average 32% for PD and 27% for BEZ), but
the combination (PB) suppressed colonies by 63% to 80% (average
70%) The Bliss formula was used to assess for synergy. PD and BEZ
were synergistic in all cell lines: BxPC-3 (expected 37% of colonies
surviving, observed 34%), CFPAC-1 (expected 27%, observed 21%),
CAPAN-2 (expected 51%, observed 33%), MiaPACA-2 (expected
67%, observed 20%), and PANC-1 (expected 74%, observed 37%).
When the two ER cell lines were compared with their respective
parent cell line, there appeared even fewer colonies formed in ER
compared with parent cell lines (Supplementary Figure 4). Pooled
from four experiments, there was significantly lower efficacy for PB
compared with EY in the drug-sensitive BxPC-3 cell line only
(Figure 4B). However, the three other cell lines showed significantly
higher efficacy in PB compared with EY. In both ER cell lines,
downstream CBs (EB and PB) suppressed colonies more than the
respective parent cell lines, and significant differential responses were
seen for all three CBs between PANC-1 and PANC-ER [P = .014
(EY), .004 (EB) and b .001 (PB)] as well as for PB between BxPC-3
and BxPC-ER (P = .001).
Finally, the effect of drug combinations on cell migration was
tested because PI3K/Akt/mTOR has an important role in cancer cell
migration [22,23]. Figure 5A shows an illustrative example of theeffect of EY CB compared with ERL single blockade and control.
Whereas cancer cells quickly apposed each other by 6 hours under
control conditions, ERL delayed this process to 18 to 24 hours,
whereas EY CB completely halted this process. When the three CBs
were compared, they all significantly reduced migration to a similar
extent particularly in BxPC-3 (50%-70%, all Ps b .01) and BxPC-ER
(70%-90%, all Ps b .001) and less so in PANC-1 (20%-30%, all Ps b
.05) and PANC-ER (20%-30%, all Ps b .05). PB performed slightly
better than the other CBs, but this has not reached statistical
significance (Figure 5B). Of note, in both BxPC-3 and BxPC-ER, the
contour of the trend with all CBs was nearly completely flat beyond
20 hours compared with the near-exponential trend under control
conditions. Although PB was slightly advantageous compared with
EY and EB, it is clear that all CBs effectively suppressed migration of
PDAC cells.
Discussion
The MAPK-PAM pathways are signaling cascades of kinases that play
critical roles in cancer growth and proliferation [24]. The MAPK
pathway is constitutively activated by mutated K-Ras through the
intrinsic binding of GTPs in PDAC. K-Ras activates downstream
signaling Raf (B-Raf, Raf-1, A-Raf), ERK, and MEK, which
translocate into the cell nucleus, regulate transcription factors, and
alter gene expression with the end result of promoting cell growth
[24,25]. K-Ras mutation is present in increasing rates in advanced
stages of pancreatic intraepithelial neoplasia (PanIN)—the precursor
of PDAC—from 30% to 38% (PanIA), 31% to 44% (PanIB), and
73% (PanIN2) to 83% (PanIN3) and are prevalent in over 90% of
PDAC [1]. The PAM pathway, on the other hand, is an integral
pathway in cell growth and survival, responsible for important cellular
functions such as protein synthesis, cell cycle progression, prolifer-
ation, and survival [26,27]. In PDAC, class I PI3-kinase is highly
overexpressed in 70% of pancreatic ductal adenocarcinoma [28]. Akt,
the direct downstream signal of the PI3K complex, is also consistently
activated in over 40% of PDAC cell lines [29]. Once activated, Akt
relieves the inhibition effect of TSC-1 and TSC-2 on the mTORC-1
and -2 complexes, leading to activation of direct downstream S6 and
4EBP-1, which are intricately involved in cell cycle and mRNA
translation [30,31] (Supplementary Figure 1). Critical to the function
of these two pathways is the myriad of upstream regulators including
EGFR, IGF1R, and many others (e.g., MET or HGFR, HER2,
VEGF-R, PDGF-R, Kit). Importantly, there is also significant
interaction between the MAPK and PAM pathways at multiple levels,
with interactions reported for K-Ras/GSK3β (a downstream effector
of Akt), K-Ras/PTEN via TGF-β, and K-Ras/PI3K and PDK1
[32–35]. The multiple interactions and feedback loops certainly add a
layer of complexity to the biology of these pathways and suggest that
these signaling cascades should be viewed as a signaling network
rather than a simple linear, unidirectional cascade [36]. Over the last
decades, numerous novel inhibitors that inhibit the PAM pathways
have now become available; many of these have entered into clinical
studies, and a number of these have already been registered
(Supplementary Figure 5). However, on their own, PAM pathway
inhibitors have limited efficacy, and much effort is continuing to
explore the best strategies to combine these agents [37]. Because a lot
more is now understood about interactions between MAPK and PAM
pathways, the current preclinical study was undertaken to explore
upstream and downstream horizontal blockades in pancreatic cancer.
The results of this study are summarized in Supplementary Table 2.
Figure 5.Migration assays: (A) Representative photographs of migration assays showing the effect of ERL 10 μMand the EY combination
(10 μM/5 μM) on BxPC-3 cell line. The rate of migration was measured as the rates of increase in confluence after a uniform scratch was
made by the 96-pin wound maker. (B) Effect of three drug combinations at medium concentrations (ERL 5 μM and BYL 5 μM, ERL 5 μM
and BEZ 0.2 μM, PD 10 μM and BEZ 0.2 μM) on migration of the two pairs of parent and ER cell lines.
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additional role of the downstream mediator mTOR in the
cross-interaction between EGFR/MAPK and PAM pathways. For
this reason, BEZ235—a dual PI3K/mTOR inhibitor—was chosenfor in vitro experiments to directly compare with the PI3K inhibitor
BYL719 in CB experiments. Western blotting experiments showed
that BEZ-containing regimens (EB, PB) were more effective in
attenuating pS6 than the BYL-containing regimen (EY), as expected
434 Co-inhibition of MAPK and PI3K/Akt/mTOR Pathways Wong et al. Neoplasia Vol. 18, No. 7, 2016for a dual PI3K/mTOR inhibitor. In addition, in a representative
example, these two CBs were also able to better suppress pERK and
abrogate the pAkt signals in the two pairs of parent and ER cell lines,
with statistically significant reduction shown in PANC-ER. This
suggests that mTOR has a defined role in the interaction of
MAPK-PAM pathways and that downstream CB is capable of
switching off molecular signals of a cell line upregulated in PAM
pathway. Further evidence for this came from cell proliferation and
clonogenic survival experiments where significant synergy between
ERL and BEZ was demonstrated in four out of five primary
pancreatic cancer cell lines compared with only one out of five cell
lines with significant synergy for the ERL-BYL combination and
another cell line with possible antagonism. Although PD and BEZ
were only significantly synergistic in two out of five cell lines, the SIs
closely approximated those of ERL and BEZ. In the clonogenic assay
experiments, all five PDAC cell lines showed significant synergy for
this combination. Overall, these observations reinforced the close
interaction between EGFR-downstream MAPK and PAM pathways
via mTOR.
The second objective of the study was to further examine the
mechanism of oncogenic dependence in PDAC cell lines. Previously,
two primary cell lines that acquired resistance to EGFR (BxPC-ER
and PANC-ER) had demonstrated upregulated AKT2 and pAkt [16].
These in turn showed hypersensitivity when treated with EGFR and
PI3K but not EGFR and IGF1R co-inhibition [16]. The current study
sought to assess the differential effect of downstream MAPK/PAM
pathway blockade on ER compared with parental cell lines. Significant
differences were observed between ER and parent cell lines in cell cycle
activity and clonogenic survival (PANC-1 and PANC-ER with all
combinations) but not in migration assays. Cell survival and cell cycle
are dominant functions of the PAMpathway viamTOR [20,21], so this
may explain the significant differential response detected in these assays,
pointing toward oncogenic dependence in these mechanisms. On the
other hand, no differential patterns were shown in migration assay.
Migration assay by its nature studied the immediate effect of treatment
within the first 30 to 40 hours in contrast to cell proliferation and cell
cycle assays (72 hours). As such, there may not be sufficient time for
differential responses to be shown in the migration assay. In addition,
migration is a highly complex cellular function that relies on numerous
molecular mechanisms as well as cell-to-cell interaction rather than a
sole molecular pathway [22,38,39]. In any case, these findings reinforce
the notion that drug resistance can be overcome by co-targeting the
original and the dominant onocogenic escape pathway, andmay suggest
a mechanism for achieving this through the abrogation of the molecular
pathway (PAM pathway via mTOR) that the drug-resistant cell lines
become addicted to.
Finally, this study sought to compare the efficacy between the three
upstream and downstream MAPK-PAM CB regimens. In primary
cell lines, cell proliferation assays showed increased drug efficacy in
the order PB N EB N EY. Significant improvement in efficacy with PB
compared with EY was demonstrated in all five PDAC cell lines. In
the paired ER and parental cell line studies, there were also suggestive
trends of increasing efficacy in cell cycle assays characterized by a
decreasing trend in SPF (EY 33%-69%, EB 27%-50%, PB 23%-41%),
in apoptosis assays characterized by increasing necrosis/apoptosis
(EY 31%-65%, EB 41%-73%, PB 56%-80%), and in clonogenic
assays with decreased colonies with the exception of BxPC-3 (EY
17%-61%, EB 5%-39%, PB 2%-36%). There was a significantly
greater improvement with PB compared with EY shown on all fourparent:resistant cell line pairs in the clonogenic assay and in PANC-ER
only in the cell cycle assay. Potential explanations of the efficacy of dual
downstreamblockade in PDAC include the facts that K-Rasmutation is
present in 90% of PDAC [1] and that K-Ras activates the canonical
MAPKpathway via Raf (B-Raf, Raf-1, A-Raf), ERK, andMEK [24] but
also activates the PAM pathway directly via PI3K or indirectly through
mediators such as GSK3β [32,35]. Although toxicity is clearly not able
to be adequately explored in preclinical studies, these findings support
clinical development of dual inhibitors with downstream blockade of
MAPK and PAM in PDAC, which reinforces existing evidence in this
field [40–42].
In summary, this study finds close interaction between MAPK and
PAM pathways via mTOR in pancreatic cancer, reinforcing that drug
resistance may be overcome by inhibition of oncogenic-dependent
pathways, and suggests dual MEK and PI3K/mTOR blockade as an
attractive therapeutic target in pancreatic cancer.
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